Identification of an HLA-A*0201-restricted cytotoxic
T lymphocyte epitope from the lung carcinoma antigen, Lengsin

MUNEHIDE NAKATSUGAWA1, KAZUTAKA HORIE1, TOSHIKI YOSHIKAWA1, MANAMI SHIMOMURA1,
YAMATO KIKUCHI1, NORIKO SAKEMURA1, SHIRO SUZUKI1, DAISUKE NOBUOKA1,
YOSHIHIKO HIROHASHI2, TOSHIHIKO TORIGOE2, KENJI HARADA3, HIDEO TAKASU3,
NORIYUKI SATO2 and TETSUYA NAKATSURA1

1Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative
Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwano, Kashiwa, Chiba 277-8577; 2Department
of Pathology, Sapporo Medical University School of Medicine, South-1, West-17, Chuo-ku, Sapporo 060-8556;
3Dainippon Sumitomo Pharma Co., Ltd., 6-8 Doshomachi 2-chome, Chuo-ku, Osaka 541-0045, Japan

Received April 27, 2011; Accepted June 2, 2011

DOI: 10.3892/ijo.2011.1089

Abstract. Lengsin is an eye lens protein with a glutamine synthetase domain. We previously identified this protein as
a lung carcinoma antigen through cDNA microarray analysis. Lengsin protein is overexpressed irrespective of the histological
type of lung carcinoma, but not in normal tissues other than the lens. Therefore, to significantly extend the use of Lengsin-
based T-cell immunotherapies for the treatment of patients with lung carcinoma, we searched for HLA-A*0201-restricted epi-
topes from this protein by screening predicted Lengsin-derived candidate peptides for the induction of tumor-reactive CTLs. Four Lengsin-derived peptides were selected by computerized algorithm based on a permissive HLA-A*0201 binding motif, and were used to immunize HLA-A*0201 transgenic (HHD) mice. Two of the immunizing peptides, Lengsin(206-215)(FIYDFCIIFGV) and Lengsin(270-279)(FLPPEFGISSA), induced peptide-specific cytotoxic T lymphocytes (CTLs) in HHD mice, and thus were used to stimulate human peripheral blood lymphocytes in vitro. Lengsin(206-215) and Lengsin (270-279) also induced human peptide-specific CTLs, and we were able to generate Lengsin(206-215)- and Lengsin(270-
279)-specific CTL clones. The Lengsin(270-279)-specific CTL clone specifically recognized peptide-pulsed T2 cells, COS-7
cells expressing HLA-A*0201 and Lengsin, and HLA-A*0201/Lengsin+ lung carcinoma cells in an HLA-A*0201-restricted manner. On the other hand, the Lengsin(206-215)-specific CTL clone failed to recognize HLA-A*0201+/Lengsin+ target
cells in the absence of cognate peptide. These results suggest that Lengsin(270-279) is naturally processed and presented by
HLA-A*0201 molecules on the surface of lung carcinoma cells and may be a new target for antigen-specific T-cell immuno-
therapy against lung cancer.

Introduction

Lung cancer is the leading cause of cancer death in the world (1). Current chemotherapy and radiotherapy regimens provide
a limited survival benefit and are often toxic as well as ineffective. Tumor antigen-specific T-cell immunotherapy is a
promising new approach to cancer treatment that is more effective and less toxic. Recent studies have shown that the adoptive
transfer of normal peripheral lymphocytes genetically modified by the insertion of tumor-reactive T-cell receptors (TCRs) can
mediate in vivo complete regression in patients with metastatic melanoma (2,3), and synovial cell sarcoma (4). Identification
of naturally presented peptides derived from tumor-associated antigens on the surface of tumor cells, which can induce
peptide-specific and tumor-reactive cytotoxic CD8+ T cells (CTLs), is required for antigen-specific T-cell immunotherapy
including TCR gene transfer therapy as the therapeutic target. To date, many immunogenic CTL epitopes in the context
of HLA-A*0201, which is the predominant subtype in most ethnic groups (5), have been identified by reverse immunology
approach (6-8). In addition, H-2Dm”, β2m”, HLA-A*0201 monochain transgenic (HHD) mouse is a useful animal model
for assessing the ability of individual peptides to induce HLA-A*0201-restricted CTL response (9-15). Previously, we
used genome-wide cDNA microarray analysis to identify a novel lung cancer antigen, Lengsin, as a potential target for
immunotherapy (16). Lengsin protein is overexpressed irrespective of the histological type of lung carcinoma, but not in
normal tissues other than the lens. Because the eye lens is an immune-privileged site (17,18), similar to the case of the testis,
Lengsin can be an attractive target for tumor antigen-specific immunotherapy, as with cancer-testis antigens.

Correspondence to: Dr Tetsuya Nakatsura, Section Head, Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwano, Kashiwa, Chiba 277-8577, Japan
E-mail: tnakatsu@east.ncc.go.jp

Key words: Lengsin, lung carcinoma antigen, cytotoxic T lymphocyte epitope, HLA-A*0201-restricted
In the current study, we attempted to identify Lengsin-derived CTL epitope via a reverse immunology approach. We studied four Lengsin-derived peptides with the HLA-A*0201 binding motif selected by HLA-peptide binding predictions of the Bioinformatics and Molecular Analysis Section (BIMAS) program and evaluated their ability to provoke peptide-specific CTL responses in HLA-A*0201 transgenic (HHD) mice, and then we induced and generated peptide-specific CTL clones from peripheral blood lymphocytes of HLA-A*0201 healthy donors. We report here that the Lengsin(270-279) (FLPEFGISSA)-specific human CTL clones specifically recognize peptide-pulsed T2 cells, COS-7 transfectants expressing HLA-A*0201 and Lengsin, and HLA-A*0201/Lengsin tumor cells in an HLA-A*0201-restricted manner.

Materials and methods

Animals. HLA-A*0201-transgenic HHD mice were described previously (9). H-2D<sup>b</sup>-<i>β</i>m<sup>-/-</sup>-m-HLA-A*2.1 (<i>α</i>1<i>α</i>2)-H-2D<sup>b</sup>-<i>α</i>3 transmembrane cytoplasmic) (HHD) monoclonal construct gene were generated at the Département SIDA-Rétrovirus, Unité d’Immunité Cellulaire Antivirale, Institut Pasteur, France and kindly provided by Dr F.A. Lemonnier. The mice were kept under specific pathogen-free conditions. Mouse experiments were approved by the Animal Research Committee of National Cancer Center Hospital East.

Peptides and plasmids. Human Lengsin-derived peptides (purity >90%) sharing the amino acid sequences with mouse Lengsin and carrying binding motifs for HLA-A*0201-encoded molecules, were identified using HLA-peptide binding predictions of the Bioinformatics and Molecular Analysis Section (BIMAS) program (http://bimas.dct.nih.gov/molbio/ala_bind/index.html). We purchased a total of four Lengsin-derived peptides carrying HLA-A*0201 binding motifs (Table 1) from GeneWorld (Tokyo, Japan). HIV-gag (77-85) (SLYNTYATL) peptide was used as an irrelevant peptide in murine and human CTL assays. Full-length Lengsin cDNA was obtained from a human lung carcinoma cell line and subcloned into pcDNA3.1 vector (Invitrogen) as described previously (16). Expression vector pcDNA3.1 containing the HLA-A*0201 cDNA was provided by Riken BRC (19). The HLA-A*0201 cDNA was subcloned into pIRES-puro vector (Clontech) for stable transfection.

Table I. The affinity of Lengsin-derived peptides for HLA-A*0201 molecules.

<table>
<thead>
<tr>
<th>Peptide (position)</th>
<th>Amino acid length</th>
<th>Peptide sequence</th>
<th>Binding score&lt;sup&gt;a&lt;/sup&gt;</th>
<th>% MFI increase&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lengsin(149-158)</td>
<td>10</td>
<td>LMPHELSTFRV</td>
<td>2030</td>
<td>79</td>
</tr>
<tr>
<td>Lengsin(206-215)</td>
<td>10</td>
<td>FIYDFCIFGV</td>
<td>7699</td>
<td>65</td>
</tr>
<tr>
<td>Lengsin(270-279)</td>
<td>10</td>
<td>FLPEFGISSA</td>
<td>215</td>
<td>75</td>
</tr>
<tr>
<td>Lengsin(347-355)</td>
<td>9</td>
<td>GLKKHSAAL</td>
<td>79</td>
<td>44</td>
</tr>
<tr>
<td>HIV-gag(77-85)</td>
<td>9</td>
<td>SLYNTYATL</td>
<td>103</td>
<td>66</td>
</tr>
</tbody>
</table>

<sup>a</sup>Binding scores were estimated by using BIMAS software (http://www-bimas.cit.nih.gov/molbio/ala_bind/). <sup>b</sup>Percent MFI increase of HLA-A*0201 molecules on T2 cells. Percent MFI increase = (MFI with sample peptide - MFI without peptide)/MFI without peptide x 100. See the HLA-A*0201-binding assay in Materials and methods.

Cell lines. Human liver cancer cell line SK-Hep-1 (HLA-A*0201/Lengsin) and simian COS-7 (HLA-A*0201/Lengsin) were obtained from the American Type Culture Collection (Manassas, VA, USA). Human lung carcinoma cell line 1-87 (HLA-A*0201/Lengsin) was obtained from the Cell Resource Center for Biomedical Research, Tohoku University (Sendai, Japan). T2 is a lymphoblastoid cell line that lacks TAP function and has HLA-A*0201 molecules that can be easily loaded with exogenous peptides. 1-87 and SK-Hep-1 were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco). T2 was cultured in RPMI supplemented with 10% heat-inactivated FBS. The 1-87-A*0201 cell line (HLA-A*0201/Lengsin<sup>b</sup>) was obtained by stable transfection of 1-87 with HLA-A*0201 cDNA, and the SK-Hep-1-Lengsin (HLA-A*0201/Lengsin<sup>b</sup>) cell line was obtained by stable transfection of SK-Hep-1 with full-length Lengsin cDNA using FuGene<sup>®</sup> HD (Roche Applied Science). 1-87-A*0201 and SK-Hep-1-Lengsin was cultured in DMEM supplemented with 10% heat-inactivated FBS containing 1 µg/ml puromycin (Sigma-Aldrich) and 1 mg/ml G418 (Gibco), respectively. In addition, COS-7 cells transiently expressing HLA-A*0201<sup>b</sup> and/ or full-length Lengsin as the target cells were generated by cotransfection with pcDNA3.1 vector encoding these proteins using Lipofectamine<sup><sup>®</sup></sup> 2000 (Invitrogen).

HLA-A*0201-binding assay. To determine the binding ability of the predicted peptides to HLA-A*0201 molecules, an in vitro cellular binding assay was performed as previously reported (20). Briefly, after incubation of T2 cells in culture medium at 26°C for 18 h, cells (2x10<sup>5</sup>) were washed with PBS and suspended in 1 ml of Opti-MEM<sup>®</sup> (Invitrogen) with or without 100 µg of peptide, followed by incubation at 26°C for 3 h and then at 37°C for 3 h. After washing with PBS, HLA-A*0201 expression was measured by flow cytometry using FITC-conjugated HLA-A2-specific monoclonal antibody (mAb) (BB7.2; BioLegend), and mean fluorescence intensity (MFI) was recorded. Percent MFI increase was calculated as follows: Percent MFI increase = (MFI with the given peptide - MFI without peptide)/MFI without peptide x 100.

Induction of Lengsin-derived peptide-specific CTLs in HHD mice. In vivo immunization of mice and in vitro stimulation of primed spleen cells were performed as previously described (12). Briefly, bone marrow (BM) cells (2x10<sup>6</sup>) from HHD mice
were cultured in RPMI-1640 supplemented with 10% FBS, together with granulocyte macrophage colony-stimulating factor (5 ng/ml) and 2-ME (0.8 ng/ml) for 7 days in 10-cm plastic dishes, and these bone-marrow-derived dendritic cells (BM-DCs) were pulsed with a mixture of the four Lengsin-derived peptides carrying HLA-A'0201 binding motifs (1 µM for each peptide) at 37°C for 2 h. We primed the HHD mice with this syngeneic BM-DC vaccine (5x10^6/mouse) into the peritoneal cavity once a week for two weeks. Seven days after the last immunization, the spleens were collected and CD4-negative spleen cells were isolated by negative selection with anti-CD4 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) to exclude any non-specific IFN-γ production by CD4+ spleen cells cocultured with the BM-DCs. The CD4-negative spleen cells (2x10^6/well) were restimulated with syngeneic BM-DCs (2x10^5/well) pulsed once with the mixture of peptides in vitro. Six days later, the frequency of cells producing IFN-γ/1x10^6 CD4-negative spleen cells upon stimulation with syngeneic BM-DCs (5x10^5/well) pulsed with each peptide or the irrelevant peptide, was evaluated in an enzyme-linked immunosorbent spot (ELISPOT) assay as described below.

**Generation of Lengsin peptide-specific CD8+ T cell clones from human PBMCs.** This study was approved by the Ethics Committee of the National Cancer Center, and conforms to the ethical guidelines of the Declaration of Helsinki (1995). CTL clones were generated using the methods described previously with some modifications (21). Blood samples were collected from HLA-A'0201+ healthy donors, after informed consent was obtained. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by Ficoll-Paque (GE Healthcare) density gradient centrifugation. PBMCs were cultured (5x10^6 cells/well) with 1 or 0.1 µg/ml Lengsin-derived peptide in AIM-V medium supplemented with 10% human AB serum, 10 U/ml recombinant human interleukin (rhIL)-2 (Chiron, Emeryville, CA, USA) once a week for two or three weeks and supplemented with 10 U/ml rhIL-2 between stimulations. Seven days after the last stimulation, CD8+ T cells were isolated using a CD8 T-cell isolation kit (Miltenyi Biotec) and plated at 3, 1 and 0.3 cells/well in 96-well round-bottom plates with 5 µg/ml PHA-P (Wako, Tokyo, Japan), 200 U/ml rhIL-2 and 8x10^4 cells/well allogeneic irradiated (100 Gy) PBMCs. Proliferating T cell clones were screened for peptide-specific IFN-γ production by ELISPOT assay using T2 cells pulsed with or without the immunizing peptide.

**Enzyme-linked immunosorbent spot (ELISPOT) assay.** Specific IFN-γ secretion of murine and human CTLs in response to stimulator cells was assayed using the IFN-γ ELISPOT Kit (BD Biosciences) according to the manufacturer's instructions. Stimulator cells were pulsed with or without peptide for 1 h at 37°C and then washed thrice. Responder cells (5x10^5/well) were incubated with stimulator cells for 20 h. In blocking experiments, peptide-pulsed T2 or tumor cells were preincubated with HLA-A2-specific mAb (BB7.2) or isotype control mAb (m1gG2b; BioLegend) for 1 h. The resulting spots were counted using an ELI PHOTO counter (Minerva Tech, Tokyo, Japan).

**Cytotoxicity assay.** To measure cytolytic activity of the CTL clones, calcein AM release-based cytotoxic cell assay was performed as described previously (22,23). Briefly, 2x10^5 target cells were labeled with green fluorescent probe calcein AM at 37°C for 30 min and washed thrice. Target cells were pulsed with or without peptide for 1 h at 37°C and washed thrice. Effector cells were incubated with 1x10^5 target cells for 4 h at the indicated effector-to-target (E:T) ratios. The fluorescence emitted by target cells was measured using a Terascan system (Minerva Tech, Tokyo, Japan) before and after coincubation with effector cells. Percentage of specific lysis was determined as: (experimental release - spontaneous release)/(maximal release - spontaneous release) x 100.

**Results**

**Identification of Lengsin-derived peptide binding to HLA-A’0201 molecules.** As the candidates of HLA-A’0201-restricted and human Lengsin-derived CTL epitopes, we selected four peptides having high predicted HLA-A’0201-binding scores calculated using the BIMAS software program, and we evaluated their binding ability to HLA-A’0201 molecules (Table I). All four peptides were able to bind to HLA-A’0201 molecules.

**Induction of CTL response against the Lengsin-derived peptides in HHD mice.** To evaluate the immunogenic potential of the four predicted HLA-A’0201-binding peptides derived from Lengsin, we immunized HHD mice with BM-DCs pulsed with a mixture of the four peptides. The results of ELISPOT assays revealed that the CD4-negative spleen cells stimulated in vitro with BM-DCs efficiently produced IFN-γ when pulsed with the Lengsin(206-215) or Lengsin(270-279) but not with Lengsin(149-158), Lengsin(347-355), or HIV-gag peptides (Fig. 1). Similar results were obtained in three independent experiments. These results suggest that Lengsin(206-215) and Lengsin(270-279) have immunogenic potential and are able to induce peptide-specific CTLs in HHD mice.

**Generation of Lengsin-peptide-specific CTL clones from human PBMCs.** Next, we assessed the capacity of Lengsin(206-
NAKATSUGAWA et al.: IDENTIFICATION OF A NOVEL CTL EPITOPE DERIVED FROM LENGSIN

215) or Lengsin(270-279) to generate peptide-specific CTLs in vitro from human PBMCs of HLA-A*0201+ healthy donors. CTLs were induced by two or three weekly in vitro stimulations with the Lengsin(206-215) or Lengsin(270-279) and were subsequently cloned by limiting dilution. We obtained one CTL clone (clone 3C9 derived from healthy donor (HD)1), which was able to specifically recognize T2 cells pulsed with Lengsin(206-215) but not T2 cells pulsed with irrelevant HIV-gag peptide, and two CTL clones (clone 1A1 derived from HD3 and clone 1G12 derived from HD2), which were able to specifically recognize T2 cells pulsed with Lengsin(270-279) but not T2 cells pulsed with HIV-gag peptide, assessed by IFN-γ ELISPOT assay (Fig. 2A). These three CTL clones had a CD3+CD8−CD4− phenotype determined by flow cytometric
analysis (data not shown). In addition, IFN-γ production of CTL clones against cognate peptide-pulsed T2 cells was inhibited by HLA-A2-specific mAb, but not isotype control mAb, indicating that recognition by these CTL clones was HLA-A2 restricted (Fig. 2B). Moreover, we evaluated the cytolytic activity of these CTL clones against cognate peptide-pulsed T2 cells (Fig. 2C). Lengsin(206-215)-specific CTL clone 3C9 could specifically lyse Lengsin(206-215)-pulsed T2 cells but not Lengsin(270-279)- or HIV-gag peptide-pulsed T2 cells, and Lengsin(270-279)-specific CTL clones 1A1 and 1G12 could specifically lyse Lengsin(270-279)-pulsed T2 cells but not Lengsin(206-215)- or HIV-gag peptide-pulsed T2 cells. These results suggest that Lengsin(206-215) or Lengsin(270-279) can induce peptide-specific CTLs from human PBMCs, and Lengsin(206-215)- or Lengsin(270-279)-specific CTL clones specifically recognize cognate peptide-pulsed T2 cells in an HLA-A*0201-restricted manner.

Functional avidity of Lengsin-specific CTL clones. To evaluate the functional avidity of Lengsin(206-215)- or Lengsin(270-279)-specific CTL clones for cognate peptide-MHC ligands, peptide titration experiments were performed in cytotoxicity assay (Fig. 3). The peptide concentration required to obtain half-maximal lysis (EC50) by CTL clones 3C9, 1A1 and 1G12 was 11.0, 11.2 and 4.0 nM, respectively. These results suggest that Lengsin(206-215)-specific CTL clones 1A1 and 1G12 have relatively higher avidity than these two clones for cognate peptide-MHC ligands.

Lengsin(270-279)-specific CTL clone recognizes Lengsin-transfected target cells in the absence of peptide, but Lengsin(206-215)-specific CTL clone fails. Next, we evaluated the ability of Lengsin(206-215)- or Lengsin(270-279)-specific CTL clones to recognize HLA-A*0201+/Lengsin* target cells. These CTL clones were incubated with COS-7 cells expressing HLA-A*0201 and/or Lengsin, SK-Hep-1-mock (HLA-A*0201/Lengsin) and SK-Hep-1-Lengsin (HLA-A*0201/Lengsin*) in the presence or absence of cognate peptide (Fig. 4). Specific IFN-γ production of Lengsin(270-279)-specific CTL clones 1A1 and 1G12 was detectable against COS-7 cells expressing both HLA-A*0201 and Lengsin, but not the non-treated, and only HLA-A*0201 or Lengsin-cDNA-transfected COS-7 cells in the absence of cognate peptide. In contrast, IFN-γ production of Lengsin(206-215)-specific CTL clone 3C9 was not detectable against COS-7 cells expressing both HLA-A*0201 and Lengsin in the absence of cognate peptide (Fig. 4A). Furthermore, specific IFN-γ production of Lengsin(270-279)-specific CTL clones 1A1 and 1G12 was detectable against both HLA-A*0201 and Lengsin-positive cell line SK-Hep-1-Lengsin (HLA-A*0201+/Lengsin*), but not Lengsin-negative SK-Hep-1-mock (HLA-A*0201+/Lengsin*) in the absence of cognate peptide (Fig. 4B). The specific IFN-γ production was blocked by HLA-A2-specific mAb, but not the isotype control, suggesting that the observed production was HLA-A2 restricted (Fig. 4C).

In contrast, IFN-γ production of Lengsin(206-215)-specific CTL clone 3C9 was not detectable against SK-Hep-1-Lengsin in the absence of cognate peptide (Fig. 4B). These results suggest that the Lengsin(270-279)-specific CTL clones can specifically recognize Lengsin-transfected HLA-A*0201+ target cells; however, the Lengsin(206-215)-specific CTL clone is unable to recognize these target cells unless Lengsin(206-215) is exogenously added.

Lengsin(270-279)-specific CTL clone also recognizes HLA-A*0201+ lung carcinoma cells endogenously expressing Lengsin. We previously reported that Lengsin was expressed in the lung carcinoma cell line 1-87 (16). In order to investigate whether Lengsin(270-279) is naturally processed and presented on the surface of lung carcinoma cells, we generated a 1-87-A0201 (HLA-A*0201+/Lengsin*) stable cell line as a target of both HLA-A*0201 and Lengsin-positive lung carcinoma cells. Lengsin(206-215)-specific CTL clone 3C9 or Lengsin(270-279)-specific CTL clone 1G12 was incubated with 1-87-mock (HLA-A*0201+/Lengsin*) or 1-87-A0201 (HLA-A*0201+/Lengsin*) in the presence or absence of cognate peptide. Lengsin(270-279)-specific CTL clone 1G12 was able to specifically recognize 1-87-A0201 (HLA-A*0201+/Lengsin*) but not the non-HLA-A*0201 cell line 1-87-mock (HLA-A*0201+/Lengsin*) in the absence of cognate peptide (Fig. 5A). The specific IFN-γ production was blocked by HLA-A2-specific mAb but not the isotype control mAb, suggesting that the observed IFN-γ production was HLA-A2 restricted
In addition, Lengsin(270-279)-specific CTL clone 1G12 was able to specifically lyse 1-87-A0201 (HLA-A*0201+/Lengsin+) (Fig. 5C). In contrast, Lengsin(206-215)-specific CTL clone 3C9 was unable to recognize and lyse 1-87-A0201 (HLA-A*0201+/Lengsin-) in the absence of cognate peptide (Fig. 5A and C). These results suggest that the Lengsin(270-279)-specific CTL clone can recognize the HLA-A*0201+ lung carcinoma cell line endogenously expressing Lengsin in an HLA-A*0201-restricted fashion; therefore, Lengsin(270-279) is naturally processed and presented by HLA-A*0201 molecules on the surface of lung carcinoma cells expressing Lengsin.

Discussion

In order to demonstrate that predicted candidate peptides are naturally presented on tumor cells, it is necessary that
peptide-specific CTL clones or lines are induced by the peptides and the CTL clones or lines specifically recognize the tumor cells. In this study, Lengsin(206-215) and Lengsin(270-279) were able to induce peptide-specific CTLs in HHD mice and humans, indicating that these peptides could be immunogenic. Especially, we were able to establish each peptide-specific CTL clone from human PBMCs. The Lengsin(270-279)-specific CTL clones specifically recognized cognate peptide-pulsed T2 cells and HLA-A*0201+ tumor cells endogenously expressing Lengsin, suggesting that Lengsin(270-279) is naturally processed and presented on the surface of Lengsin-expressing tumor cells in association with HLA-A*0201. Therefore, Lengsin(270-279) may be a new target for antigen-specific T-cell immunotherapy against lung cancer. However, the Lengsin(206-215)-specific CTL clone failed to recognize those tumor cells expressing Lengsin, although it showed efficient recognition against HLA-A*0201+ target cells in the presence of exogenously added peptide.

Figure 5. Recognition of lung carcinoma cells endogenously expressing Lengsin by Lengsin-specific CTL clones. (A) Lengsin(206-215)-specific CTL clone 3C9 or Lengsin(270-279)-specific CTL clone 1G12 (5x10^5 cells) was incubated with 1-87-mock (HLA-A*0201/Lengsin−) or 1-87-A0201 (HLA-A*0201+/Lengsin+) pulsed or not for 1 h with 1 µM indicated peptides. IFN-γ-producing CTLs were detected by IFN-γ ELISPOT. (B) Blocking experiments were performed using HLA-A2-specific mAb (BB7.2) or isotype control mAb (mIgG2b). Lengsin(270-279)-specific CTL clone 1G12 (5x10^5 cells) was incubated with 1-87-A0201 (HLA-A*0201+/Lengsin+) as stimulator cells. IFN-γ-producing CTLs were detected by IFN-γ ELISPOT. (C) Specific lysis of lung carcinoma cell lines 1-87-mock (HLA-A*0201/Lengsin−, △) and 1-87-A0201 (HLA-A*0201+/Lengsin+, ■) by Lengsin(206-215)-specific CTL clone 3C9 or Lengsin(270-279)-specific CTL clone 1G12. Results are expressed as the mean ± SD.
CTLs induced by reverse immunology approaches often fail to recognize HLA-matched tumor targets expressing specific genes (24-27). Possible explanations with respect to each factor of the induced CTLs and the targeted tumor cells seem plausible.

With regard to the factor of induced CTLs, they might not have sufficient avidity to recognize a limited number of naturally presented peptides on the surface of tumor cells (28-30). Consequently, it is necessary to induce high-avidity tumor-reactive CTLs. Reported methods for inducing high-avidity CTLs include stimulation with low concentration of peptides (31,32), with three costimulatory molecules (B7-1, ICAM-1 and LFA-3) (33), cultured with IL-12 (34) or IL-15 (35), and using allogeneic PBMCs as a source of CTLs (36-38). Additionally, it is very important to demonstrate recognition of tumor cells by CTL clones but not bulk CTL populations in terms of specificity. The bulk CTL populations that were used may have contained distinct CTL clones, some of which were responsible for peptide recognition and others that accounted for the apparent tumor reactivity (39). In fact, it has been reported that tETERT(540-548) is controversial as to its status as a naturally processed and presented peptide due to different results depending on assessment of bulk CTL populations (11,40) or CTL clones (41-43). Therefore, it is also important to establish highly avid tumor-reactive CTL clones for evaluation of specific tumor reactivity of CTLs. Melanoma-associated antigen-specific high-avidity tumor-reactive CTL clones have been generated by CD107a-guided sorting (44). In our laboratory, we recently generated GPC3(144-152)-specific high-avidity tumor-reactive CTL clones by CD107a-guided sorting from PBMCs of patients vaccinated with GPC3(144-152) peptide (45). In this study, we evaluated tumor reactivity using CTL clones, but not bulk CTL populations. Lengsin(206-215)-specific high-avidity tumor-reactive CTL clones could possibly be induced and generated by further studies using the above methods.

With regard to the factor of targeted tumor cells, the predicted candidate peptides might not be processed and presented on the surface of tumor cells. In this study, Lengsin(206-215)-specific CTL clone 3C9 and Lengsin(270-279)-specific CTL clone 1A1 showed approximately similar avidity in peptide titration experiments. CTL clone 1A1 recognized target cells expressing Lengsin; however, CTL clone 3C9 failed. For this reason, Lengsin(206-215) might not be processed and presented on target cells. Peptides presented by MHC class I molecules are usually derived from intracellular proteins that are degraded by the proteasome (46). In contrast, by using the proteasome inhibitor lactacystin, it has happened that the expression of naturally processed peptide is sharply increased by a proteasome-independent mechanism, resulting in enhanced recognition by CTL clones (25,47-49). It would be interesting to examine whether Lengsin(206-215) or Lengsin(270-279) are naturally presented peptides on the surface of tumor cells. In addition, a new presented peptide derived from Lengsin might be detected.

Acknowledgements

This work was supported in part by a Grant-in-Aid for Clinical Research from the Ministry of Health, Labour and Welfare, Japan. Human HLA-A*02011 cDNA (DDB no. 2866) was provided by RIKEN BRC through the National Bio-Resources Project of MEXT, Japan.

References


